Melatonin reverses flow shear stress‐induced injury in bone marrow mesenchymal stem cells via activation of AMP‐activated protein kinase signaling
- 27 December 2015
- journal article
- research article
- Published by Wiley in Journal of Pineal Research
- Vol. 60 (2) , 228-241
Abstract
Tissue‐engineered heart valves (TEHVs) are a promising treatment for valvular heart disease, although their application is limited by high flow shear stress (FSS). Melatonin has a wide range of physiological functions and is currently under clinical investigation for expanded applications; moreover, extensive protective effects on the cardiovascular system have been reported. In this study, we investigated the protection conferred by melatonin supplementation against FSS‐induced injury in bone marrow mesenchymal stem cells (BMSCs) and elucidated the potential mechanism in this process. Melatonin markedly reduced BMSC apoptotic death in a concentration‐dependent manner while increasing the levels of transforming growth factor β (TGF‐β), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), platelet‐derived growth factor (PDGF) and B‐cell lymphoma 2 (Bcl2), and decreasing those of Bcl‐2‐associated X protein (Bax), p53 upregulated modulator of apoptosis (PUMA), and caspase 3. Notably, melatonin exerted its protective effects by upregulating the phosphorylation of adenosine monophosphate‐activated protein kinase (AMPK), which promotes acetyl‐CoA carboxylase (ACC) phosphorylation. Further molecular experiments revealed that luzindole, a nonselective antagonist of melatonin receptors, blocked the anti‐FSS injury (anti‐FSSI) effects of melatonin. Inhibition of AMPK by Compound C also counteracted the protective effects of melatonin, suggesting that melatonin reverses FSSI in BMSCs through the AMPK‐dependent pathway. Overall, our findings indicate that melatonin contributes to the amelioration of FSS‐induced BMSC injury by activating melatonin receptors and AMPK/ACC signaling. Our findings may provide a basis for the design of more effective strategies that promote the use of TEHCs in patients.Keywords
Funding Information
- National Natural Science Foundation of China (81422004, 81500263, 81470480, 81470477, 81100137, 81100081)
- China Postdoctoral Science Foundation (2015M572681)
This publication has 69 references indexed in Scilit:
- Melatonin ameliorates vascular endothelial dysfunction, inflammation, and atherosclerosis by suppressing the TLR4/NF‐κB system in high‐fat‐fed rabbitsJournal of Pineal Research, 2013
- Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxiaJournal of Pineal Research, 2013
- JAK2/STAT3 activation by melatonin attenuates the mitochondrial oxidative damage induced by myocardial ischemia/reperfusion injuryJournal of Pineal Research, 2013
- Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVR‐induced depletion, and protects against the formation of DNA damage (8‐hydroxy‐2'‐deoxyguanosine) in ex vivo human skinJournal of Pineal Research, 2012
- Atorvastatin prevents mesenchymal stem cells from hypoxia and serum-free injury through activating amp-activated protein kinaseInternational Journal of Cardiology, 2011
- Chronic melatonin consumption prevents obesity‐related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet‐induced obesityJournal of Pineal Research, 2010
- Effect of Fluid Shear Stress on Cardiomyogenic Differentiation of Rat Bone Marrow Mesenchymal Stem CellsArchives of Medical Research, 2010
- Activation of AMP-activated Protein Kinase α1 Alleviates Endothelial Cell Apoptosis by Increasing the Expression of Anti-apoptotic Proteins Bcl-2 and SurvivinJournal of Biological Chemistry, 2010
- Valvular Heart Disease: Diagnosis and ManagementMayo Clinic Proceedings, 2010
- Enhancement of Mesenchymal Stem Cell Attachment to Decellularized Porcine Aortic Valve Scaffold by In Vitro Coating with Antibody Against CD90: A Preliminary Study on Antibody-Modified Tissue-Engineered Heart ValveTissue Engineering Part A, 2009